Have any questions?
+44 1234 567 890
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. Pacira is also advancing several clinical-stage product candidates including PCRX-201, an osteoarthritis gene therapy program that has completed a Phase 1 clinical trial with 72 knee osteoarthritis patients and was originally acquired from GQ Bio.
Pacira is an investor in GQ Bio and the companies are collaborating in product and manufacturing process development.